Philip Zakas

Title: Innovations by Inventor Philip Zakas: A Focus on Gene Therapy

Introduction

Philip Zakas, an accomplished inventor based in Waltham, MA, has made significant contributions to the field of gene therapy. With one patent to his name, Zakas focuses on innovative solutions for treating genetic conditions and metabolic disorders, particularly related to the liver.

Latest Patents

The latest patent filed by Philip Zakas is titled "Nucleic acid molecules and uses thereof for non-viral gene therapy." This patent describes nucleic acid molecules that comprise a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. The target sequence can encode a microRNA (miRNA) and/or a therapeutic protein. Notably, the therapeutic protein may include a clotting factor, a growth factor, a hormone, a cytokine, an antibody, or a fragment thereof. The invention also specifies that the ITRs may be derived from a non-adeno-associated virus (AAV). Additionally, the patent outlines methods of treating metabolic disorders of the liver by administering the nucleic acid molecule or a polypeptide encoded by it.

Career Highlights

Philip Zakas is currently employed at Bioverativ Therapeutics Inc., a company that focuses on innovative therapy solutions for hemophilia and other blood disorders. His role at Bioverativ allows him to apply his expertise in the development of advanced gene therapies, making a profound impact on patient care.

Collaborations

Throughout his career, Philip Zakas has collaborated with esteemed colleagues such as Tongyao Liu and Alexey Seregin. These partnerships in research and development exemplify a commitment to advancing gene therapy and improving treatment outcomes for patients with genetic disorders.

Conclusion

In conclusion, Philip Zakas stands out as a notable inventor in the biotech industry, especially in the realm of gene therapy. His innovative approach, highlighted by his patent on nucleic acid molecules for non-viral gene therapy, showcases his dedication to developing transformative treatments for metabolic disorders. As he continues his work at Bioverativ Therapeutics Inc., Zakas is poised to make further advancements in this critical field.